A Phase II Study of Weekly Irinotecan and Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer

Clinical Cancer Research

Volumn 9, Issue 16 I, 2003, Pages 5909-5914

  Han, Ji Youn ^a   Lee, Dae Ho ^a   Kim, Hyae Young ^a   Kim, Eun A ^a   Lee, Jae Jin ^a   Ju, So Young ^a   Shin, Eun Hee ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0347364777     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Stathopoulos, G. P., Rigatos, S., and Malamos, N. A. Paclitaxel combined with cisplatin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cisplatin. Oncol. Rep., 6: 797-800, 1999.
2. Bunn, P. A. J., and Kelly, K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res., 4: 1087-1100, 1998.
3. Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., Coughlin, S., Kim, Y., and Berille, J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol., 18: 2095-2103, 2000.
4. Fossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L., Miller, V., Lee, J. S., Moore, M., Gandara, D., Karp, D., Vokes, E., Kris, M., Kim, Y., Gamza, F., and Hammershaimb, L. Randomized Phase III trial of docetaxel versus vinorelbine or ifos-famide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol., 18: 2354-2362, 2000.
5. Fossella, F. V., Lee, J. S., Shin, D. M., Calayag, M., Huber, M., Perez-Soler, R., Murphy, W. K., Lippman, S., Benner, S., Glisson, B., et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J. Clin. Oncol., 13: 645-651, 1995.
6. Lavelle, F., Bissery, M. C., Andre, S., Roquet, F., and Riou, J. F. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin. Oncol., 23 (Suppl. 3): 11-20, 1996.
7. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
8. Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., Elfring, G. L., and Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 343: 905-914, 2000.
9. Van Cutsem, E., Rougier, P., Droz, J. P., Marty, M., and Bleiberg, H. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer resistant to 5-FU. Proc. Am. Soc. Clin. Oncol., 16: 268a, 1997.
10. Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., Bonneterre, J., Adenis, A., Seitz, J. F., Ganem, G., Namer, M., Conroy, T., Negrier, S., Merrouche, Y., Burki, F., Mousseau, M., Herait, P., and Mahjoubi, M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol., 15: 251-260, 1997.
11. Schuller, J., Cassidy, J., Dumont, E., Roos, B., Durston, S., Banken, L., Utoh, M., Mori, K., Weidekamm, E., and Reigner, B. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother. Pharmacol., 34: 293-296, 2000.
12. Twelves, C., Harper, P., Va, C. E., Thibault, A., Shelygin, Y. A., Burger, H. U., Allman, D., and Osterwalder, B. A Phase III trial (S014796) of Xeloda (capecitabine) in previously untreated advanced/ metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 263a, 1999.
13. John, C., Pazdur, R., Thibault, A., Maroun, J., Weaver, C., Michaela, J., Harrison, E., and Griffin, T. A Phase III trial of Xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 265a, 1999.
14. Pavillard, V., Formento, P., Rostagno, P., Formento, J. L., Fischel, J. L., Francoual, M., Etienne, M. C., and Milano, G. Combination of irinotecan (CPT-11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem. Pharmacol., 56: 1315-1322, 1998.
15. Jordan, K., Grothey, A., Kellner, A., Constantin, C., Dietrich, G., Schlichting, C., Mantovani, L., Kroening, H., Hagen, V., Gutberlet, K., et al. Randomized Phase II trial of capecitabine plus irinotecan versus capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer (ACRC): results of an interim analysis. Proc. Am. Soc. Clin. Oncol., 21: 103b, 2002.
16. Cassata, A., Stani, S. C., Alù, M., Procopio, G., Cortinovis, D., Beretta, E., Ferrario, E., Longarini, R., Baldini, A., Lambiase, A., et al. Ongoing Phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol., 20: 144a, 2001.
17. Van Cutsem, E., Findlay, M., Osterwalder, B., Kocha, W., Dalley, D., Pazdur, R., Cassidy, J., Dirix, L., Twelves, C., Allman, D., Seitz, J. F., Scholmerich, J., Burger, H. U., and Verweij, J. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized Phase II study. J. Clin. Oncol., 18: 1337-1345, 2000.
18. WHO. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publ. No. 48. Geneva: WHO, 1979.
19. Simon, R. Optimal two-stage designs for Phase II clinical trials. Control. Clin. Trials, 10: 1-10, 1998.
20. Kaplan, E. S., and Meier, P. Non-parametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
21. Hryniuk, W., and Bush, H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol., 2: 1281-1288, 1984.
22. Negoro, S., Fukuoka, M., Niitani, H., Suzuki, A., Nakabayashi, T., Kimura, M., Motomiya, M., Kurita, Y., Hasegawa, K., Kuriyama, T., et al. A Phase II study of CPT- 11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group (in Japanese). Gan To Kagaku Ryoho, 18: 1013-1019, 1991.
23. Nakai, H., Fukuoka, M., Furuse, K., Nakao, I., Yoshimori, K., Ogura, T., Hara, N., Sakata, Y., Saito, H., Hasegawa, K., et al. An early Phase II study of CPT-11 in primary lung cancer (in Japanese). Gan To Kagaku Ryoho, 18: 607-612, 1991.
24. Huisman, C., Smit, E. F., Giaccone, G., and Postmus, P. E. Second-line chemotherapy in relapsing or refractory non-small cell lung cancer: a review. J. Clin. Oncol., 18: 3722-3730, 2000.
25. Sawada, N., Ishikawa, T., Fukase, Y., Nishida, M., Yoshikubo, T., and Ishitsuka, H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin. Cancer Res., 4: 1013-1019, 1998.
26. Morita, T., Matsuzaki, A., and Tokue, A. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int. J. Cancer, 92: 451-456, 2001.
27. O'Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J. P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W. Y., Mauriac, L., Twelves, C., Van Hazel, G., Verma, S., and Leonard, R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol., 20: 2812-2823, 2002.
28. Han, J. Y., Lee, D. H., Kim, H. Y., Chun, J. H., Yoon, S. M., Lee, H. K., Lee, S. Y., Shin, E. H., Yoo, H. J., and Lee, J. S. A Phase II study of weekly docetaxel plus capecitabine for patients with advanced non-small cell lung cancer (NSCLC). Cancer (Phila.), 98: 1918-1924, 2003.
29. Francis, P. A., Rigas, J. R., Kris, M. G., Pisters, K. M., Orazem, J. P., Woolley, K. J., and Heelan, R. T. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J. Clin. Oncol., 12: 1232-1237, 1997.
30. Falcone, A., Di Paolo, A., Masi, G., Allegrini, G., Danesi, R., Lencioni, M., Pfanner, E., Comis, S., Del Tacca, M., and Conte, P. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J. Clin. Oncol., 19: 3456-3462, 2001.